Europe faces chronic antibiotic shortages driven by rising production costs and rigid low-price policies that make supplying off-patent antibiotics economically unviable. The Director General of Medicines for Europe talks about these market dynamics and the need to reform pricing and procurement policies, including through the EU’s Critical Medicines Act.
Read the comment of our Director General and full Article below.